clinical trial · NCT04749368
Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, ChronicBRII-835 (VIR-2218)BRII-179 (VBI-2601) with IFN-αBRII-179 (VBI-2601)
brief summary
This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection
started
Apr 12, 2021
primary completion
Jul 4, 2023
completion
Jul 4, 2023
last updated
Jun 18, 2024
official title
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol